Abstract
PURPOSE: Cytology fails to detect neoplastic cells in approximately 40–50% of malignant pleural effusions, which commonly accompany lung adenocarcinomas. Published reports of the diagnostic sensitivity of various tumor markers are inconsistent. Reports on Her-2/neu in lung adenocarcinoma-associated malignant pleural effusion, for example, differ markedly (72% vs. 10%). In addition, optimal cutoff points have not been determined. To clarify contrasting reports and maximize diagnostic efforts, we evaluated the diagnostic sensitivity, specificity and optimal cutoff points for Her-2/neu, Cyfra 21-1 and carcinoembryonic antigen (CEA) in distinguishing lung adenocarcinoma-associated malignant from benign pleural effusions.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call